Rallybio said it discontinued its RLYB212 program following disappointing results in a phase 2 trial. Pharmacokinetic data demonstrated an inability of the RLYB212 dose regimen to achieve predicted ...

The company is dropping its former lead molecule in favor of another antibody, RLYB116, which is being developed for a ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare ...

Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.

Simultaneously, Rallybio has initiated a Phase 2 clinical trial for RLYB212, a potential treatment for Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), a rare condition affecting fetuses ...